SG11202003398SA - Adenovirus vectors and uses thereof - Google Patents

Adenovirus vectors and uses thereof

Info

Publication number
SG11202003398SA
SG11202003398SA SG11202003398SA SG11202003398SA SG11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA SG 11202003398S A SG11202003398S A SG 11202003398SA
Authority
SG
Singapore
Prior art keywords
adenovirus vectors
adenovirus
vectors
Prior art date
Application number
SG11202003398SA
Inventor
Taco Uil
Soumitra Roy
Jort Vellinga
Selina Khan
Jerôme Custers
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11202003398SA publication Critical patent/SG11202003398SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202003398SA 2017-10-31 2018-10-30 Adenovirus vectors and uses thereof SG11202003398SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199350 2017-10-31
PCT/EP2018/079719 WO2019086461A1 (en) 2017-10-31 2018-10-30 Adenovirus vectors and uses thereof

Publications (1)

Publication Number Publication Date
SG11202003398SA true SG11202003398SA (en) 2020-05-28

Family

ID=60413038

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003398SA SG11202003398SA (en) 2017-10-31 2018-10-30 Adenovirus vectors and uses thereof

Country Status (13)

Country Link
US (1) US11459583B2 (en)
EP (1) EP3704256A1 (en)
JP (1) JP7229239B2 (en)
KR (1) KR20200074988A (en)
CN (1) CN111295449B (en)
AU (1) AU2018359494A1 (en)
BR (1) BR112020008435A2 (en)
CA (1) CA3077630A1 (en)
EA (1) EA202091039A1 (en)
IL (1) IL274218A (en)
MX (1) MX2020004490A (en)
SG (1) SG11202003398SA (en)
WO (1) WO2019086461A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7054527B2 (en) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ High-throughput assay to measure adenovirus replication kinetics
JP7015551B2 (en) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ Exogenous gene expression in therapeutic adenovirus to minimize its impact on viral dynamics
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
BR112019026126A2 (en) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. poxvirus vectors encoding HIV antigens and methods of using them
BR112022014808A2 (en) 2020-01-31 2022-09-20 Beth Israel Deaconess Medical Ct Inc COMPOSITIONS AND METHODS FOR VACCINES TO PREVENT AND TREAT CORONAVIRUS-SARS-COV-2 INFECTION
IL298055A (en) 2020-05-11 2023-01-01 Janssen Pharmaceuticals Inc Stabilized coronavirus spike protein fusion proteins
JP2023531554A (en) 2020-06-29 2023-07-24 ヤンセン ファッシンズ アンド プリベンション ベーフェー Vaccine Combinations Against Respiratory Syncytial Virus Infection
CA3187149A1 (en) 2020-07-06 2022-01-13 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
JP2023551743A (en) * 2021-01-21 2023-12-12 株式会社 セリッド Novel adenoviral vectors that do not contain replication-competent adenoviruses and uses thereof
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
WO2022175477A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb antigens
EP4314019A2 (en) 2021-04-01 2024-02-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023026182A1 (en) 2021-08-24 2023-03-02 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
ATE278794T1 (en) 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
NZ530245A (en) 2001-06-22 2007-04-27 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
ATE447037T1 (en) 2002-04-25 2009-11-15 Crucell Holland Bv MEANS AND METHOD FOR PRODUCING ADENOVIRUS VECTORS
US8232255B2 (en) 2002-10-23 2012-07-31 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
PL1711518T3 (en) 2004-01-23 2010-06-30 St Di Richerche Di Biologia Molecolare P Angeletti S P A Chimpanzee adenovirus vaccine carriers
WO2006040330A2 (en) * 2004-10-13 2006-04-20 Crucell Holland B.V. Improved adenoviral vectors and uses thereof
DE602005025512D1 (en) 2004-10-13 2011-02-03 Crucell Holland Bv IMPROVED ADENOVIRUS VECTORS AND THEIR USE
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
SI2220241T1 (en) 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus comprising a Simian E Adenovirus SAdV-39 capsid hexon protein and uses thereof
DK2350268T3 (en) 2008-11-03 2015-03-23 Crucell Holland Bv PROCEDURE FOR PRODUCING ADENOVIRUS VECTORS
BRPI1008018A2 (en) 2009-02-02 2016-03-15 Okairos Ag simian adenovirus nucleic acids and amino acid sequences, vectors containing and use thereof
US8865182B2 (en) 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
KR101820980B1 (en) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Method for the production of Ad26 adenoviral vectors
US9526777B2 (en) 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
WO2013016591A1 (en) 2011-07-26 2013-01-31 Zuvachem, Inc. High efficiency isoprene synthases produced by protein engineering
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof

Also Published As

Publication number Publication date
CN111295449B (en) 2023-12-05
MX2020004490A (en) 2020-08-13
AU2018359494A1 (en) 2020-04-23
KR20200074988A (en) 2020-06-25
BR112020008435A2 (en) 2020-11-17
WO2019086461A1 (en) 2019-05-09
CN111295449A (en) 2020-06-16
CA3077630A1 (en) 2019-05-09
EA202091039A1 (en) 2020-08-10
JP2021500899A (en) 2021-01-14
US11459583B2 (en) 2022-10-04
IL274218A (en) 2020-06-30
US20200347405A1 (en) 2020-11-05
JP7229239B2 (en) 2023-02-27
EP3704256A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
IL274218A (en) Adenovirus vectors and uses thereof
ZA202002191B (en) Adenovirus and uses thereof
ZA202002184B (en) Adenovirus and uses thereof
IL273236A (en) Pyrazolopyrimidinone compounds and uses thereof
IL273510A (en) Combination therapies and uses thereof
IL293377B1 (en) Hsd17b13 variants and uses thereof
PT3265571T (en) Multiple vector system and uses thereof
GB201713765D0 (en) Modified adenovirus
IL268593A (en) Polypeptide variants and uses thereof
GB201715052D0 (en) Vectors
IL274220A (en) Adenovirus and uses thereof
GB201717524D0 (en) Vectors
EP3480212C0 (en) Il13ralpha2 peptide and its uses
IL275211A (en) Fast and partition-resilient blockchains
IL273671A (en) Cornulin (crnn) variants and uses thereof
IL269836B (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
ZA201905513B (en) Rorgamma modulators and uses thereof
ZA201905511B (en) Rorgamma modulators and uses thereof
PT3250234T (en) Recombinant mdv1 and the uses thereof
IL274278A (en) Vectors
IL269843B (en) Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
GB201705927D0 (en) Vector
GB201711971D0 (en) Vectors
GB201706219D0 (en) Modified adenovirus
GB201712266D0 (en) polypeptides and uses thereof